Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
- About
PRFX 
Painreform Ltd (PRFX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/05/2025: PRFX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $12
1 Year Target Price $12
| 0 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -21.84% | Avg. Invested days 7 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 12/05/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.87M USD | Price to earnings Ratio 0.03 | 1Y Target Price 12 |
Price to earnings Ratio 0.03 | 1Y Target Price 12 | ||
Volume (30-day avg) 1 | Beta 0.55 | 52 Weeks Range 0.80 - 16.63 | Updated Date 11/14/2025 |
52 Weeks Range 0.80 - 16.63 | Updated Date 11/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 29.9 |
Earnings Date
Report Date 2025-11-27 | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -36.19% | Return on Equity (TTM) -127.65% |
Valuation
Trailing PE 0.03 | Forward PE - | Enterprise Value 338075 | Price to Sales(TTM) - |
Enterprise Value 338075 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -2.32 | Shares Outstanding 2013141 | Shares Floating 1834374 |
Shares Outstanding 2013141 | Shares Floating 1834374 | ||
Percent Insiders 9.4 | Percent Institutions 2.45 |
Upturn AI SWOT
Painreform Ltd
Company Overview
History and Background
PainReform Ltd. is an Israeli medical device company specializing in the development and commercialization of innovative products for pain management. Founded in 2009, the company's primary focus has been on its flagship product, the Depo-Blockeru2122 injection, a long-acting local anesthetic designed to provide post-operative pain relief. Key milestones include regulatory approvals and the initiation of clinical trials in various regions.
Core Business Areas
- Pain Management Solutions: Development and commercialization of long-acting injectable anesthetics for post-operative pain management. This includes their proprietary Depo-Blockeru2122 technology.
Leadership and Structure
PainReform Ltd. is led by a management team with expertise in the medical device and pharmaceutical industries. Specific names and detailed organizational structure would require access to current company filings and investor relations information.
Top Products and Market Share
Key Offerings
- Depo-Blockeru2122: A proprietary, non-opioid injectable anesthetic designed to provide sustained post-operative pain relief for various surgical procedures. Market share data for this specific product is not publicly available, but its competitors include traditional local anesthetics (e.g., lidocaine, bupivacaine) and other extended-release pain management solutions from companies like Pacira BioSciences (EXPAREL).
Market Dynamics
Industry Overview
The pain management market is a significant and growing sector within healthcare, driven by an aging population, an increase in surgical procedures, and a growing demand for non-opioid alternatives to manage chronic and acute pain. The market is characterized by intense competition and a strong emphasis on innovation and clinical efficacy.
Positioning
PainReform aims to position itself as a provider of advanced, long-acting local anesthetics that can reduce opioid reliance and improve patient recovery. Its competitive advantage lies in its proprietary delivery system and the potential for extended pain relief duration.
Total Addressable Market (TAM)
The global pain management market is valued in the tens of billions of dollars and is projected to continue growing. PainReform's TAM is focused on the segment of the market addressing post-operative pain management with long-acting local anesthetics. The company is positioned to capture a portion of this market by offering an alternative to existing solutions.
Upturn SWOT Analysis
Strengths
- Proprietary technology for extended pain relief.
- Potential for a non-opioid solution to pain management.
- Focus on a significant unmet need in post-operative care.
Weaknesses
- Limited commercialization history and brand recognition.
- Reliance on regulatory approvals and market adoption.
- Competition from established players with extensive product portfolios.
Opportunities
- Growing demand for non-opioid pain management options.
- Expansion into new geographic markets.
- Partnerships with healthcare providers and surgical centers.
- Further development of its technology for other applications.
Threats
- Intense competition from both generic and innovative pain relief products.
- Regulatory hurdles and lengthy approval processes.
- Pricing pressures from payers and healthcare systems.
- Emergence of new pain management technologies.
Competitors and Market Share
Key Competitors
- Pacira BioSciences (PCRX)
- Local Anesthetic Manufacturers (e.g., Pfizer, Teva)
- Other Pain Management Device/Drug Developers
Competitive Landscape
PainReform faces competition from established pharmaceutical companies with broad portfolios of pain management drugs and innovative biotech firms developing novel therapies. Its advantage lies in its focused approach to a specific need (long-acting post-operative pain relief) with a potentially differentiated product. However, overcoming the market penetration of existing solutions and demonstrating clear clinical and economic benefits will be critical.
Growth Trajectory and Initiatives
Historical Growth: Historically, PainReform's growth trajectory has been centered on the development and regulatory progression of its core technology. This involves scientific research, preclinical and clinical studies, and seeking necessary approvals.
Future Projections: Future growth projections are contingent on successful commercialization of Depo-Blockeru2122, market adoption by healthcare providers, and expansion into new indications or geographies. Analyst estimates would be available in financial reports.
Recent Initiatives: Recent initiatives likely involve advancing clinical trials, securing regulatory approvals in key markets, and building out its commercial infrastructure in anticipation of product launch and market entry.
Summary
PainReform Ltd. is a promising medical device company focused on long-acting pain management solutions. Its core product, Depo-Blockeru2122, addresses the significant market demand for non-opioid post-operative pain relief. While the company possesses innovative technology and operates in a growing market, it faces considerable challenges related to competition, regulatory approvals, and the need for market adoption. Its success hinges on effectively navigating these hurdles and demonstrating the clinical and economic value of its offerings.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company investor relations materials (when available).
- Securities and Exchange Commission (SEC) filings (e.g., 10-K, 10-Q, S-1).
- Industry research reports.
- Financial news outlets.
Disclaimers:
This JSON output is based on publicly available information and general industry knowledge. Specific financial figures, market share data, and detailed competitive analyses for PainReform Ltd. may be subject to change and require access to real-time financial data and proprietary research. This information is for informational purposes only and not intended as financial advice.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Painreform Ltd
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2020-09-01 | Interim CEO & Executive Chairman Dr. Ehud Geller Ph.D. | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 2 | Website https://www.painreform.com |
Full time employees 2 | Website https://www.painreform.com | ||
PainReform Ltd., a clinical stage specialty pharmaceutical company, focuses on the reformulation of established therapeutics and provides an extended period of post-surgical pain relief in Israel. It develops PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia, as well as in Phase 3 clinical trial for pain treatment of patients undergoing bunionectomy and pain treatment of hernia repair operations. The company was incorporated in 2007 and is based in Tel Aviv, Israel.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.